These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 39103353)

  • 21. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.
    Richards MW; Burgess SG; Poon E; Carstensen A; Eilers M; Chesler L; Bayliss R
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13726-13731. PubMed ID: 27837025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation.
    Quintanal-Villalonga A; Kawasaki K; Redin E; Uddin F; Rakhade S; Durani V; Sabet A; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Kinyua D; Zhong H; Mello BP; Ciampricotti M; Bhanot UK; Linkov I; Qiu J; Patel RA; Morrissey C; Mehta S; Barnes J; Haffner MC; Socci ND; Koche RP; de Stanchina E; Molina-Pinelo S; Salehi S; Yu HA; Chan JM; Rudin CM
    Signal Transduct Target Ther; 2024 Jul; 9(1):189. PubMed ID: 39054323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity.
    Paul I; Ahmed SF; Bhowmik A; Deb S; Ghosh MK
    Oncogene; 2013 Mar; 32(10):1284-95. PubMed ID: 22543587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
    Brady NJ; Bagadion AM; Singh R; Conteduca V; Van Emmenis L; Arceci E; Pakula H; Carelli R; Khani F; Bakht M; Sigouros M; Bareja R; Sboner A; Elemento O; Tagawa S; Nanus DM; Loda M; Beltran H; Robinson B; Rickman DS
    Nat Commun; 2021 Jun; 12(1):3372. PubMed ID: 34099734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer.
    Sulsenti R; Scialpi GB; Frossi B; Botti L; Ferri R; Tripodi I; Piva A; Sangaletti S; Pernici D; Cancila V; Romeo F; Chiodoni C; Lecis D; Bianchi F; Fischetti I; Enriquez C; Crivelli F; Bregni M; Renne G; Pece S; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
    Cancer Immunol Res; 2024 Sep; 12(9):1147-1169. PubMed ID: 38869181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer.
    German B; Alaiwi SA; Ho KL; Nanda JS; Fonseca MA; Burkhart DL; Sheahan AV; Bergom HE; Morel KL; Beltran H; Hwang JH; Freedman ML; Lawrenson K; Ellis L
    Cancer Res Commun; 2024 Sep; 4(9):2295-2307. PubMed ID: 39113611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers.
    Elhasasna H; Khan R; Bhanumathy KK; Vizeacoumar FS; Walke P; Bautista M; Dahiya DK; Maranda V; Patel H; Balagopal A; Alli N; Krishnan A; Freywald A; Vizeacoumar FJ
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
    Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
    Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
    Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
    Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
    Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
    J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
    Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
    Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
    Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.
    Brockmann M; Poon E; Berry T; Carstensen A; Deubzer HE; Rycak L; Jamin Y; Thway K; Robinson SP; Roels F; Witt O; Fischer M; Chesler L; Eilers M
    Cancer Cell; 2013 Jul; 24(1):75-89. PubMed ID: 23792191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer.
    Ton AT; Foo J; Singh K; Lee J; Kalyta A; Morin H; Perez C; Ban F; Leblanc E; Lallous N; Cherkasov A
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
    Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteostasis or Aging: Let the CHIPs Fall Where They May.
    Branicky R; Hekimi S
    Dev Cell; 2017 Apr; 41(2):126-128. PubMed ID: 28441527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.
    Otto T; Horn S; Brockmann M; Eilers U; Schüttrumpf L; Popov N; Kenney AM; Schulte JH; Beijersbergen R; Christiansen H; Berwanger B; Eilers M
    Cancer Cell; 2009 Jan; 15(1):67-78. PubMed ID: 19111882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stabilization of AURKA by the E3 ubiquitin ligase CBLC in lung adenocarcinoma.
    Hong SY; Lu YC; Hsiao SH; Kao YR; Lee MH; Lin YP; Wang CY; Wu CW
    Oncogene; 2022 Mar; 41(13):1907-1917. PubMed ID: 35149839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.
    Sun Y; Liu PY; Scarlett CJ; Malyukova A; Liu B; Marshall GM; MacKenzie KL; Biankin AV; Liu T
    Oncogene; 2014 Jun; 33(23):2987-94. PubMed ID: 23812427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The E3 ubiquitin ligase HUWE1 acts through the N-Myc-DLL1-NOTCH1 signaling axis to suppress glioblastoma progression.
    Yuan Y; Wang LH; Zhao XX; Wang J; Zhang MS; Ma QH; Wei S; Yan ZX; Cheng Y; Chen XQ; Zou HB; Ge J; Wang Y; Zhang X; Cui YH; Luo T; Bian XW
    Cancer Commun (Lond); 2022 Sep; 42(9):868-886. PubMed ID: 35848447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.